News - Asia-Pacific, India

Filter

Current filters:

Asia-PacificIndia

Popular Filters

1 to 25 of 36 results

Indian regulator seeks to address the nation’s substandard drugs problem

Indian regulator seeks to address the nation’s substandard drugs problem

22-04-2014

In what is something of an indictment of India’s pharmaceutical industry, the Drug Controller General…

Asia-PacificIndiaPharmaceuticalProductionRegulation

Indian govt plans to support a competitive pharma sector, especially for SMEs

Indian govt plans to support a competitive pharma sector, especially for SMEs

14-04-2014

In a bid to strengthen the existing infrastructure facilities and to enable the Indian pharmaceutical…

Asia-PacificGenericsIndiaMarkets & MarketingPoliticsProduction

India’s IPAB upholds Pfizer’s Detrol patent

India’s IPAB upholds Pfizer’s Detrol patent

27-03-2014

In a positive development for US drug giant Pfizer, India's Intellectual Property Appellate Board (IPAB)…

Asia-PacificDetrolGenito-urinaryIndiaPatentsPfizerPharmaceuticalRanbaxy Laboratories

India urged to take action on unregulated tuberculosis drug sales

23-03-2014

Although cases of tuberculosis are dropping in Europe, as is the incidence in the USA, an extremely slower…

Antibiotics and Infectious diseasesAsia-PacificHealthcareIndiaPharmaceuticalResearch

Asia-Pacific NSCLC market to reach $2.9 billion by 2019

Asia-Pacific NSCLC market to reach $2.9 billion by 2019

18-03-2014

The non-small cell lung cancer (NSCLC) therapeutics market value in the Asia-Pacific (APAC) region -…

Asia-PacificAustraliaChinaIndiaJapanMarkets & MarketingOncologyPharmaceutical

Sun Pharma latest Indian generic drugmaker to fall foul of US FDA

Sun Pharma latest Indian generic drugmaker to fall foul of US FDA

14-03-2014

Even as India-based drug majors Ranbaxy and Wockhardt reel under the impact of US Food and Drug Administration…

Asia-PacificGenericsIndiaProductionRegulation

Mylan pushes further into India, introducing critical care segment

Mylan pushes further into India, introducing critical care segment

12-03-2014

US generics major Mylan says its Indian subsidiary has launched a Critical Care segment in India. The…

AmbisomeAntibiotics and Infectious diseasesAsia-PacificGenericsIndiaMarkets & MarketingMylan Laboratories

GSK increases stake in Indian Pharma subsidiary to 75%

GSK increases stake in Indian Pharma subsidiary to 75%

10-03-2014

UK pharma giant GlaxoSmithKline says that, following the voluntary open offer undertaken by its Indian…

Asia-PacificGlaxoSmithKlineIndiaMergers & AcquisitionsPharmaceutical

India now making moves into pharma innovation

India now making moves into pharma innovation

03-03-2014

In what must be seen as a significant change in focus, India is now seeing a surge of innovative research…

Asia-PacificBiosimilarsIndiaMarkets & MarketingPharmaceuticalResearch

Natco prevails in Indian Copaxone patent dispute with Teva

Natco prevails in Indian Copaxone patent dispute with Teva

03-03-2014

Hyderabad, India-based Natco Pharma has won a significant patent battle against Israeli generics giant…

Asia-PacificCopaxoneGenericsIndiaNatco PharmaPatents & Trade marksTeva Pharmaceutical Industries

Ranbaxy temporarily suspends shipments from Toansa and Dewas plants

25-02-2014

Indian drugmaker Ranbaxy Laboratories has announced in a letter to the Stock Exchange that it has temporarily…

Asia-PacificDaiichi SankyoGenericsIndiaProductionRanbaxy Laboratories

Indian drugmakers readying for next “Patent cliff”

24-02-2014

The strategic drug reviews, as well as mergers and acquisitions – such as Actavis buying out Forest…

Asia-PacificGenericsIndiaMergers & AcquisitionsPatentsPharmaceuticalRegulation

Merck & Co partners with Cipla for Indian marketing of raltegravir

Merck & Co partners with Cipla for Indian marketing of raltegravir

21-02-2014

US pharma giant Merck & Co, known as MSD outside North America, has announced the formation of an India-specific…

Anti-viralsAsia-PacificCiplaIndiaIsentressMarkets & MarketingMerck & CoPharmaceuticalRaltegravir Tablets

India’s patents moves could see particular uncertainty for diabetes sector

India’s patents moves could see particular uncertainty for diabetes sector

17-02-2014

The Indian government's decision to review patented drugs by multinationals, to allow for the manufacture…

Abbott LaboratoriesAsia-PacificDiabetesEli LillyIndiaMarkets & MarketingMerck & CoNovo NordiskPatentsPharmaceutical

Roche sues Biocon and Mylan over Herceptin biosimilar; US puts pressure on India over IP

Roche sues Biocon and Mylan over Herceptin biosimilar; US puts pressure on India over IP

10-02-2014

Swiss pharma major Roche’s Indian subsidiary has sued Bangalore-based Biocon and US generics firm Mylan…

Asia-PacificBioconBiosimilarsCanmabHerceptinHertrazIndiaLegalMylan LaboratoriesOncologyPatentsPharmaceuticalRegulationRoche

Regulatory update on Indian clinical research approval timelines

04-02-2014

The Drug Controller General of India (DCGI) has provided written confirmation to the pharmaceutical industry…

Asia-PacificIndiaPharmaceuticalRegulationResearch

Mylan debuts Hertraz, first Herceptin biosimilar, in India

Mylan debuts Hertraz, first Herceptin biosimilar, in India

03-02-2014

US generics major Mylan has launched the world's first trastuzumab biosimilar in India. The product,…

Asia-PacificBioconBiosimilarsGenericsHerceptinHertrazIndiaMarkets & MarketingMylan LaboratoriesOncologyRoche

Pharma multinationals facing more pricing problems in India

Pharma multinationals facing more pricing problems in India

03-02-2014

Even as a battle royal appears to be brewing between India's drug price regulator, the National Pharma…

Asia-PacificAstraZenecaFinancialGlaxoSmithKlineIndiaNovartisPfizerPharmaceuticalPricing

Mylan gets exclusive rights to distribute Gilead branded drugs in India

Mylan gets exclusive rights to distribute Gilead branded drugs in India

31-01-2014

US generics major Mylan says its India-based subsidiary has been named) exclusive branded medicines business…

AmbisomeAnti-viralsAsia-PacificBiotechnologyGilead SciencesIndiaMarkets & MarketingMylan LaboratoriesStribildTruvadaViread

AstraZeneca in licensing deal for MALT1 inhibitors; closes Bangalore R&D site

AstraZeneca in licensing deal for MALT1 inhibitors; closes Bangalore R&D site

31-01-2014

Belgium-based VIB, a non-profit research institute in life sciences, and the Center for Drug Design and…

Asia-PacificAstraZenecaIndiaInflammatory diseasesOncologyPharmaceuticalResearchTropical diseases

Cadila pulls out of operations in Japan

Cadila pulls out of operations in Japan

28-01-2014

One of India’s largest pharmaceutical companies, Cadila Healthcare (also operating as Zydus Cadila),…

Asia-PacificFinancialIndiaPharmaceuticalZydus Cadila

1 to 25 of 36 results

Back to top